Life Sciences Archive » July, 2020

Life Sciences - July, 2020

362 articles

• Humana Hits St. Jude With Fresh Suit Over Pacemakers
• Probiotic Drug Cos. In Contempt For Violating Ad Injunction
• Nev. Tax Agency Faces Heat Over Pot Licensing Settlements
• House Panel Says Gov't Overpaid $500M For Ventilators
• Nats Catcher Can't Block His 80-Game Drug Use Suspension
• Stanford Scholar Alleged To Be Chinese Agent Wins Bail
• Teva Gets Fed. Circ. To Affirm Thyroid Patent Is Indefinite
• Valeant Pharma Settles SEC Accounting Probe For $45M
• HHS Can Cut Billions In Payments To Hospitals, DC Circ. Says
• Takeda Loses Appeal To Stop Mylan's Generic Gout Drug
• Ag Industry Wants 9th Circ. To Revisit Dicamba Rescissions
• Gov't Contracts Of The Month: Vaccines, Jets And Sanctions
• J&J Fights ERISA Suit Over Asbestos In Talcum Powder
• Alice-Axed Bovine Breeding Patent Revived At Fed. Circ.
• Market Rebound May Curb Securities Class Actions, Damages
• Out-Of-State Claims Dropped In Calif. Heart Drug Suit
• Fed. Circ.'s UT Immunity Ruling Places Licensing In Spotlight
• Glancy Prongay Seeks $18.2M In Zimmer Biomet Settlement
• Health Hires: McDermott, Goodwin, Gordon Rees
• ABA Must Seize Opportunity To Respond To Bar Exam Chaos
• Hemp Cos. Should Narrow Filings After TTAB's Stanley Ruling
• Surveying Drug Pricing Reform: The Latest Federal Activity
• Major Merger Review Moments From The 1st Half Of 2020
• 3 Developments As New Virus Deaths Continue Summer Spike
• Sanofi And GSK Face DOJ Probes Over Zantac Cancer Risk
• Bayer Antitrust Judge Fears Opening Discovery 'Floodgates'
• Irell Transactions Co-Chair Joins Reed Smith Amid Shift
• Chinese National Admits Trade Secret Theft From Ohio Lab
• Justices Told Horizon's IP Loss 'Casts A Pall' On 32K Patents
• Ex-Lawmaker Sentenced To 2 Years In Pot Bribery Scheme
• Disbarred NY Attys Settle SEC's PixarBio Merger Suit
• Skadden-Led Electric SUV Maker Leads 2 IPOs Totaling $1.3B
• FDA Warns Sellers About Unapproved Hangover Remedies
• Pfizer Biopharma JV To Go Public In $780M SPAC Union
• Humira Buyers Take AbbVie Antitrust Challenge To 7th Circ.
• PTAB Axes Antecip IP, Rejects Its Printed Publication Stance
• Colgate Can't Tweak Retirement Plan To Fight ERISA Suit
• Juul Seeks FDA Approval To Market E-Cigarettes
• How Pandemic Is Affecting The Pace Of Judicial Opinions
• COVID-19 And Design Defect Jurors' Risk Evaluations: Part 3
• Biogen Can't Block Mylan MS Drug Launch During IP Appeal
• Trade Secret Litigation Is Poised To Take Off Amid Downturn
• HIV Drug Suit Against Gilead, BMS And Janssen Trimmed
• GAO Says Most Of $17.8B In COVID-19 Deals Not Competitive
• Delaware Court Denies Medical Pot Coverage Over Work Injury
• Abbott Labs Can't Ditch Cybersecurity Suit, Worker Says
• Stericycle Shareholder Fights $11M Atty Fee Award At 7th Circ.
• Herbalife Distributors Lose Appeal To Arbitrate $1B RICO Row
• Full Fed. Circ. Won't Rehear Actelion Spinoff's Patent Term Bid
• J&J Can't Get Missouri Court To Reconsider $2.1B Talc Ruling
• COVID-19 And Design Defect Jurors' Risk Evaluations: Part 2
• Investors Inject $257M Into Early Cancer Detection Co.
• Allergan Says Proposed Class Rep Is 'Serial Litigant'
• 3 Firms Drive Go-Private Deal Valuing Italy's IMA At €3B
• 6 Steps For Law Firms Looking To Improve Their Culture
• 6th Circ. Questions Opioid Negotiation Class 'Inventiveness'
• Ex-Workers Say Quest 'Asleep At The Wheel' With 401(k) Plan
• Feds Urge Justices To Eye Dozens Of Post-Arthrex Cases
• Hand Sanitizer Can't Kill 99.99% Of Germs, Suit Says
• Brown Rudnick Can't Duck $300M Malpractice Suit
• DEA Can't Keep 9th Circ. Out Of Pot Study Fight, Doctor Says
• Coronavirus Regulations: A State-By-State Week In Review
• 3rd Circ. Affirms Class Cert. In Suboxone Antitrust Case
• Sen. Graham Pushes Tax Break Bill For PPE Repatriation
• COVID-19 And Design Defect Jurors' Risk Evaluations: Part 1
• Pharma Co. Buys CBD Wellness Brand In $20M Deal
• Sanofi, Consultant Must Face Race, Age Bias Claims In NJ
• Virtual Courts Amplify Lawyers' Corporate Spokesperson Role
• 'Pharma Bro' Blasts FTC Monopoly Suit As Overreach
• Numerosity Analysis Fix Can Improve Class Cert. Decisions
• Bayer Wants Shareholder Suit Separate From Roundup MDL
• Life Sciences Co. Grabs $110M In Series C1 Funding Round
• Radish Paste Is Not A COVID-19 Cure, LA City Atty Says
• Gilead Slams HHS' 'Perverse' Requests In HIV Drug IP Battle
• Nats Catcher Says MLB Uses 'Junk Science' Drug Tests
• Pharma Co. Wants Testosterone Drug Investor Suit Tossed
• Whistleblower, Feds Object To Sanctions In Kickback Row
• Senate GOP Unveils $1T Virus Relief Package
• FTC, AbbVie Don't Want Spat Paused Amid Justices' Review
• Garmin Says Cyberattack Knocked Fitness Trackers Offline
• 6 Firms Steer Blank-Check Co.'s $255M Deal With Pot Grower
• Heart Device Co. Investors Sue In Chancery Over Lowball Sale
• Biotech Firm Hit With Chancery Suit Over Stock Transactions
• Aveo Pharma Escapes Investors' Cancer Drug Stock-Drop Suit
• Opioid MDL Judge Won't Set Up $3B Fund For Plaintiffs' Attys
• Full Fed. Circ. Won't Revisit 'Alarming' Relistor Ruling
• Law Firms Must Note Pandemic's Outsize Impact On Women
• Trump's 'Sweeping' Drug Pricing Orders Draw Fury, Doubts
• COVID-19 Vaccine Hacking May Prompt Data Security Rethink
• 2 Firms Guide Coronavirus Vaccine Contender's US IPO Plans
• Judge Advises Freeing Amgen, Teva From Suits Over Sensipar
• 9th Circ. Kills Challenge To Calif. Pay-For-Delay Law
• Convicted Ariad Inside Trader Won't Have To Pay SEC
• AbbVie Sues To Block Dr. Reddy's Generic Leukemia Drug
• Coronavirus Q&A: Sidley Austin's FDA Group Leader
• Fed. Circ. Says UT's Immunity Can't Halt Cancer Patent Suit
• Real Estate Rumors: Metropolitan, Lincoln, Scion
• Why A Surge In Drug Pricing Litigation Is Unlikely
• Complying With China's New Human Genetic Resources Law
• Aetna Blasts Conformis For Using Patient To Force Coverage
• 7 Firms Steer 4 Upsized Biotech IPOs Raising $773M Total
• The 'Rocket Docket' Show Goes On Despite Setbacks
• Aeterna, Shareholders Reach $6.5M Hormone Drug Deal
• Green Thumb Wins TRO In Arkansas Dispensary License Fight
• Pulling Up Stakes: Hogan Lovells, White & Case, Debevoise
• Indivior To Pay $600M To Settle Suboxone Charges
• Moderna Can't Invalidate Drug-Delivery Composition Patent
• DOJ Gives Antitrust Shield To Big Pharma's Virus Info Sharing
• Serenity Faces Skeptical Judge As IP Trial With Ferring Wraps
• Taro Settles DOJ Price Fixing Charges, Will Pay $205M Penalty
• BASF, Cahill Pay $73M To Settle Claims They Hid Asbestos
• Judge To Wait On Claim Talks Result For Purdue Class Call
• Atty Wants Claims Over Failed $57M Mask Deal Tossed
• GOP Virus Aid Plan Stalls Despite Deal On PPP, Taxes, Checks
• FDA Sends New CBD Guidance To White House Budget Office
• How PTAB Reviews Examiner Errors For IPR Institution
• Lab Strikes $1.2M Deal To End Fight With UnitedHealthcare
• Pandemic Lays Bare The Inequities Inherent In The Bar Exam
• Investors Say 9th Circ. Should OK Doc Bid In Hospital Fight
• Fed. Circ. Rejects Minerva Plea To Abolish Assignor Estoppel
• Insurer Sues To Avoid Liability In Fracking Cos.' Dispute
• Special Master Rips Hagens Berman's Privilege Arguments
• GNC's Bidding Procedures OK'd After Extending Sale Timeline
• $3M Apyx Settlement In Securities Suit Gets Initial OK
• Green Thumb Says Ark. Regulators Ignoring License Rules
• Ex-Theranos CEO Seeks Grand Jury Records, Citing COVID-19
• Understanding The 5 Stages Of Mediation In A Virtual World
• Biotech Co. Must Face Securities Suit Over FDA Rejection
• Goulston Seals Tricky Loan For $700M Mass. Turnpike Project
• Novartis Whistleblower Scores $109M For Flagging Kickbacks
• Coronavirus Q&A: Baker Donelson Health Care Chairs
• ITC To Probe German-Made Eye Shot Imports For Infringement
• Pfizer Inks $1.95B Deal To Provide COVID-19 Vaccine Doses
• Trump Shifts Tone On Pandemic, Wishes Well To Epstein's Ex
• Namenda Buyers Want Cert. In Pay-For-Delay Fight
• Ariz. Residents Seek To Block Legal Pot Measure From Ballot
• Pa. Justices Revive Testimony Over Cancer-Pesticide Link
• Coronavirus Regulations: A State-By-State Week In Review
• FDA Issues Guidance For Researchers Working With Cannabis
• Dicamba Makers Ask 9th Circ. To Rehear Nixed Approvals
• 3 Firms Steer Gilead's $300M Purchase Of Cancer Biz Stake
• Pandemic May Change The Way We Design Our Courthouses
• PE Co. Says Travelers Still Dodging Coverage Of Heparin Deal
• Snap Removal Still A Good Option For Defendants — For Now
• Pay-For-Delay May Need More Evidence After 3rd Circ. Ruling
• Elanco Investor Taps Glancy Prongay To Lead Class Dispute
• Pet Products Maker Wants Online Sales Antitrust Suit Tossed
• 2 Chinese Nationals Accused Of Hacking COVID-19 Research
• CVS, Walgreens Want Out Of Blood Pressure Drug MDL
• Opioid Judge 'Concerned' About Amerisource Hiding Docs
• Blood Testing Device Co. Notches Win In Rival's False Ad Suit
• Feds Open Probe Into Imported Handheld Massage Guns
• Monsanto Loses Cancer Liability Fight In 1st Roundup Appeal
• Cannabis Regs: Mass. Floats Sweeping Update To Rules
• Theranos Judge Says Ex-CEO's Oct. Trial Date Is 'Unrealistic'
• Commerce Sets Duties On Plastic From Oman And S. Korea
• Tax Software Co. Vertex Leads 5 IPO Launches Totaling $843M
• UK Reopens Pharma Probes After COVID-19 Delays
• Mediator Confidentiality Promises Carry Serious Risks
• CureVac Scores $296M In GlaxoSmithKline Partnership
• COVID-19 IP Catch-Up: Delays, Masks & Ducks
• Tribes Say Feds Can't Dodge 'Bad Men' Opioids Suit
• To Bring Pharma Onshore, Biden Takes Aim At TCJA
• Cannabis Bill Roundup: Mo. Medical Pot Regime Takes Shape
• Perrigo Investors Can't Get Irish Tax Info For Suit
• GNC Creditors Say Ch. 11 Sale Process Moving Too Quickly
• 3rd Circ. Tosses 'Pay-To-Play' Suit Against Siemens
• How A Compliance Chief Went From Ignored To Whistleblower
• Product Liability Cases To Watch In 2020: Midyear Review
• BakerHostetler Can't Ax Suit Over Ex-Clients' Illegal Gains
• Six Firms Steer Four Health-Focused IPOs Totaling $549M
• Calif. Pay-For-Delay Law Lacks Nuance
• Brand Battles: Allergan Raises Eyebrow Over Botox TM
• The Major Antitrust Conduct Cases Of 2020 So Far
• Why FTC Needs High Court Win On Monetary Equitable Relief
• Rare Disease Biotech Nabs $400M In Financing
• PBM Group Loses Bid To Halt Okla. Law Pending Appeal
• Dreamers Bring Important Perspective To Legal Industry
• SmileDirect Loses Calif. Dental Board Antitrust Suit
• A Big Prop 65 Victory For Chemical Industry In Monsanto Case
• Gilead Tries To Shake Antitrust Suit Over Expensive HIV Drugs
• House Panel Asks Agencies To Explain COVID-19 Contracts
• Thermo Fisher Sweetens Qiagen Takeover Bid To $12.5B
• Purdue Asks Court To Say No To New Classes In Ch. 11 Case
• Pfizer, Mylan Push To Pare Down EpiPen Class Action
• 9th Circ. Skeptical Calif. Pay-For-Delay Law Poses Danger
• Okla. Pharmacy Board Fines CVS $125K For Understaffing
• These 10 Decisions Remade The Patent Landscape
• Poseida Therapeutics Taps Ex-Halozyme Atty As GC
• 6th Circ. Again Refuses To Boot Judge From Opioid MDL
• Biggest Illinois Decisions So Far In 2020: Midyear Report
• Helping Clients Overcome Financial Hurdles Mid-Litigation
• Covidien Asks 1st Circ. To Hand It Ex-Worker's Device Patents
• Convicted Ex-CEO's New Trial Bid Meets Skeptical Judge
• Serenity Expert Defends IP As Zoom Trial Testimony Wraps
• Pfizer Must Face Claims It Didn't Monitor Chantix Risks
• Fired Pot Co. Accountant Says She Had Duty To Report Error
• 5th Circ. Upholds Dallas Pill Mill Operators' Sentences
• Inclusivity Considerations For Law Firms Reopening Offices
• Prepare For DOJ's Pandemic-Related Enforcement Priorities
• C4 Therapeutics Hires Ex-Neon Atty As Legal Chief
• Elanco Divestitures Secure FTC OK For $7.6B Bayer Unit Buy
• Return-To-Work Tech Brings New Contract Issues
• COVID-19 Disruption Reshapes NJ Supply Chains
• How USPTO Examiner Type Affects Patents: Part 3
• PBM Group Goes After Rest Of Okla. Law After Partial Win
• Michael Best Builds Health Care Team With Trio From Humana
• Infringement Has Judge's Eye In Ferring-Serenity Remote Trial
• Fed. Circ. Upholds Dana-Farber's IP Inventorship Victory
• Insys Shareholders Ink Deal With Ex-CEO Over Fraud Claims
• Fed. Circ. Affirms Greatbatch's $22M Pacemaker Patent Win
• Clashes Erupt Nationwide Over High Court's Abortion Ruling
• FTC, Surescripts Debate Liu's Impact On Monopolization Case
• Pot-Focused REIT To Lease $5.5M NJ Property To Curaleaf
• Dispute Over Restitution Power Threatens FTC Antitrust Tool
• BCBS Says Generic Xyrem Delay Was Antitrust Scheme
• Tax Partner Exits Greenspoon Marder With Landmark Pot Suit
• In Their Words: Why Diversity At The Bar Is Still A Problem
• The Year's Top High Court Moments From Law360's The Term
• Improper Testimony Won Pa. Mesh Case For J&J, Panel Told
• Surprising Alliances Shape The Supreme Court Term
• 11th Circ. Again Affirms Atty's Stock Fraud Conviction
• Fla. High Court Orders More Arguments On Pot License Law
• States' Case To Be Bellwether In Generic Drug Price-Fix MDL
• 5th Circ. Upholds $905K Verdict In Diagnostic Lab Spat
• Coronavirus Regulations: A State-By-State Week In Review
• How Cosmetics Cos. Can Prepare For Growth In Class Actions
• UK Eyeing Conditions On Stryker's $4B Wright Medical Deal
• Biopharmaceutical Co. Raises $250M From RTW Investments
• Mesh Case Judge Tainted By His Mom's J&J Suit, Court Told
• FinCEN Guidance A Positive Step For Hemp Businesses
• Nektar Dodges Stock-Drop Suit Over Poor Study Results
• Aspen Offers To Slash Prices On Cancer Drugs In EU Probe
• Why Can't Female Lawyers Make Headway At The High Court?
• NY High Court Case Could Upend Litigation Finance Industry
• Law360's Supreme Court Pop Quiz
• Ex-Ferring Exec Says He Had Rival's Drug Innovation First
• Pot Tracking Service Says It Can Charge Mo. Stores Fees
• 'Unfounded Attacks' On Opioid Judge Must Fail, 6th Circ. Told
• 3rd Circ. Mulling FTC-AbbVie Pause Till High Court Acts
• 2nd Circ. Revives NewLink Investor Suit Over Cancer Drug
• The Sharpest Dissents From The Supreme Court Term
• Perrigo Investors Push For Class Action Over Irish Tax Audit
• SmileDirect Likely To Lose Calif. Dental Antitrust Suit
• 5 Compliance Lessons From Novartis' FCPA Settlement
• Six Firms Steer Five IPO Launches That Could Raise $501M
• Associates Can Prioritize Biz Development Despite Pandemic
• Mallinckrodt Aims To Nix Medicaid FCA Suit Over Acthar Gel
• Feds And Eye Product Co. Sanctioned In Kickback Suit
• The Funniest Moments Of The Supreme Court's Term
• The Chattiest Justice Of The Term Is ...
• Restasis Buyers Seek $16M Atty Fees In Antitrust Case
• Judge Boots Klamann Law Firm From DST 401(k) Plan Suit
• Should Cos. Use USPTO's New Fast-Track Appeals Program?
• Attys Should Stop Using 2 Common Cannabis Industry Terms
• Client Says Hagen Berman Pulled Fast One On Special Master
• Bitter Neighbor Sank Farm's Shot At Pot License, Suit Claims
• 11th Circ. Affirms Bulk Of Ala. Doctors' 'Pill Mill' Convictions
• COVID-19 IP Catch-Up: NY Trial Finally Starts, Texas Holds Off
• The Majority Of One: How Roberts Is Shaping The Court
• FDA To Restart On-Site Inspections Paused For Virus
• Judge 'Taken Aback' By Vivus Equity Tradeoff In Ch. 11
• Breaking Down The Vote: The High Court Term In Review
• The Firms That Won Big At The Supreme Court
• Zimmer Injury Suit Stayed During Settlement Talks
• Rite Aid Accuses 47 Generic Makers Of Price-Fixing
• 6 Firms Steer Trio Of Biotech IPOs Totaling $584M
• DuPont Will Pay $3.4M To End Texas Hazardous Waste Suit
• Let's Create An Ethical Obligation For Attys To Fight Racism
• Miss. Businessman Pleads Guilty To $288M Tricare Fraud
• New Pharma Co. Defenses For 'Innovator Liability' Claims
• AbbVie Faces Suit Over Delays In Generic Blood Pressure Med
• Possibilities If Justices Review PTAB Judge Constitutionality
• Deals On Blistering Pace In 2020 Even As Virus Fears Linger
• UK Litigation Roundup: Here's What You Missed In London
• Justices Told PTAB Constitutional Issues Persist Post-Arthrex
• Full Fed. Circ. Won't Consider Standing In Novartis Drug Case
• Ferring Experts Attack Serenity Patents In SDNY Zoom Trial
• NuVasive Spinal Fusion Patents Largely Survive PTAB Review
• 1st Circ. Affirms Pharmacists' Guilt In Meningitis Outbreak
• Feds Indict 4 In Alleged $34M Pharma Kickback Scheme
• Shearman & Sterling Taps Bird & Bird Int'l Arbitration Atty
• Patent Cases To Watch In The Second Half Of 2020
• Acreage Subsidiary To Pay $250K Fine To Mass. Pot Board
• 3rd Circ. Won't Revive NJ Doc's Suit Over Improper Training
• Mass. Pot Board Fines Cos. $550K Over Pesticide Violations
• Walgreens Wants Insurers' Overcharging Suit Tossed
• A Look At CMS' Proposed Medicaid Drug Rebate Changes
• Fed. Circ. Patent Eligibility Test Erroneously Distorts Alice
• Teva Says Securities Claims Filed Too Late In Price-Fixing Suit
• Merck Spinoff Organon Hires Ex-Sorrento, Abbott Atty As GC
• 6 Considerations When Shopping For Legal Tech Software
• Blank Check Co.'s Goodwin-Led $118M IPO Employs Odd Tact
• 'What About Federalism?' Judge Asks In 11th Circ. Dental Suit
• Ohio Ruling Adds To Insurance Uncertainty For Opioid Suits
• FTC Says Online Retailer Lied About PPE Shipping Speeds
• Wholesaler Dropped As Lead In ADHD Drug Antitrust Suit
• K&L Gates Nabs Health Care Partner From Morgan Lewis
• Group To Revise Deal For Future Claims In Monsanto MDL
• Law Firm Strategies For Publicizing Laterals Amid Lockdowns
• Bull Semen Co. Wants $5M In Fees From Antitrust Trial Win
• Bias Charge Is 'Dangerous Fiction,' Opioid MDL Judge Says
• Serenity Says Ferring Owes $389K In SDNY Zoom IP Trial
• Pharma Exec Wants Out Of Hemp Co. Shareholder Suit
• Pot Co. Accuses Pryor Cashman Of Airing Confidential Deal
• Pharma Co. Files Ch. 11 Plan Proposing Icahn Acquisition
• Botox Maker Wins First Phase Of Rival Import Investigation
• FTC Fights Shkreli's Bid To Duck Monopolization Case
• Merck, Glenmark Implore Court To Reject Zetia Class Cert.
• Bid Protest Spotlight: Limitations, Timeliness, Cost-Realism
• Judge Finds No Fraud In Vote For Melinta's Ch. 11 Plan
• Faegre Drinker Guides Medical Device Biz's $50M Financing
• Are Your Slack Communications Primed For E-Discovery?
• Judge 'Skeptical' Of Settlement For Future Roundup Claims
• Amerisource Tries To Save CEO From Opioid Bellwether Depo
• Coronavirus Regulations: A State-By-State Week In Review
• Novavax Wins $1.6B From Feds To Make COVID-19 Vaccine
• Sanofi Urges High Court To Expand Arthrex To All
• Pharma Tech Co. Asks To End Suit Against Hemp Consultant
• Generics' Bid To Limit IP Loss 'Makes No Sense,' Judge Says
• Ferring And Serenity's SDNY Patent Trial Kicks Off Over Zoom
• Cooley Steers 2 Biotechs Planning Combined $252M In IPOs
• Hogan Lovells Nabs Ex-Bristol Myers Squibb Associate GC
• Fed. Circ. Clears Amgen's Avastin Biosimilar In Notice Fight
• Digital Education Provider Joins July's Growing IPO Pipeline
• How Therapeutic Formulations Affect Medical Device Patents
• Seattle Concerned About Bayer's $820M PCB Settlements
• 6 Dispute Prevention Steps As Lawsuits Rise Amid Pandemic
• Pharmacies Can't Slip Opioid Nuisance Claims, Counties Say
• Blaszczak Ruling's Broad View Of Property May Trouble Press
• Law360 Names Top Attorneys Under 40
• Portola Says Stock Drop Was 'Reversal Of Fortune,' Not Fraud
• GSK Takes Avandia Marketing Battle To Supreme Court
• J&J Investors Seek Cert. In Asbestos Stock-Drop Suit
• As Courts Punt CBD Class Actions, Attys Wait For FDA To Act
• Entrepreneur Who Gave Tips On Dad's Pharma Co. Gets Year
• Top Delaware Cases Of 2020: A Midyear Report
• Top New Jersey Cases Of 2020: A Midyear Report
• Don't Count On PREP Act To Defend Pandemic IP Infringement
• Biotech Firms Drive IPO Rebound While 'Unicorns' Gear Up
• Gov't Contracts Of The Month: Vaccine, Radars, Submarines
• Time To Consider Percentage Rental Agreements For Lawyers
• Indirect Purchaser Antitrust Standing Heads In New Direction
• Alexion Pharmaceuticals To Pay SEC $21M Over FCPA Claims
• Novartis To Pay $729M To End 2 FCA Kickback Accusations
• Insys Execs Can't Dodge Prison During Appeal, Seek Delay
• Cook Chastises Firm For 'No-Injury' Vein Filter Bellwether
• Akorn Gets Del. Ch. 11 Disclosure OK As Plan Fight Looms
• Fed. Circ. Keeps Sandoz's Enbrel Biosimilar Off The Market
• Agendia Pays $8.25M In FCA Suit Over Delayed Cancer Tests
• Fed. Circ., Judge Nix CardioNet Heart Monitor Patent Claims
• Abbott Labs Tries To Shake ERISA Cybersecurity Suit
• Gannett Hit With $500M Libel Suit Over Antibody Test Story
• Sandoz Dodges Sanctions Bid In Antitrust Dispute
• Bausch Not Covered For Allergan Case, Insurers Say
• Portola Investor Wants Docs About $1.4B Alexion Deal
• Annexon Raises $100M To Push Autoimmune, Brain Therapies
• Indivior Wants 3rd Circ. To Undo Suboxone Class Cert.
• Skadden-Led SPAC Prices $125M IPO To Fund Biotech Buy
• Canadian Pharma Co. Wants Investors' Stock-Drop Suit Nixed
• 'Settle And Sue' Malpractice Cases Have New Clarity In Calif.
• Block & Leviton Tapped To Lead Biopharma Stock-Drop Suit